OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
86
Results
Show all
Save search
Copy query
Show results for
Unknown
(84)
Proteomics
(1)
Metabolomics
(1)
Organisms
Homo sapiens
(1)
Repository
iProX
(1)
MetaboLights
(1)
Technology Type
Mass spectrometry
(1)
Instrument Platform
Liquid Chromatography MS - Positive (LC-MS (Positive))
(1)
Liquid Chromatography MS - Negative (LC-MS (Negative))
(1)
Publication Date
2023
(1)
2019
(1)
CHEBI ID
CHEBI:89976
(1)
CHEBI:89756
(1)
CHEBI:88472
(1)
CHEBI:88400
(1)
CHEBI:138471
(1)
CHEBI:134639
(1)
CHEBI:72060
(1)
CHEBI:88658
(1)
CHEBI:136147
(1)
CHEBI:132542
(1)
CHEBI:140506
(1)
CHEBI:136214
(1)
CHEBI:136195
(1)
CHEBI:136212
(1)
CHEBI:134640
(1)
CHEBI:134597
(1)
CHEBI:89775
(1)
CHEBI:89778
(1)
CHEBI:134637
(1)
CHEBI:136101
(1)
CHEBI:85000
(1)
CHEBI:136152
(1)
CHEBI:134598
(1)
CHEBI:138448
(1)
CHEBI:136154
(1)
CHEBI:136148
(1)
CHEBI:136168
(1)
CHEBI:132544
(1)
CHEBI:132543
(1)
CHEBI:132540
(1)
Metabolite Name
PE P-18:0/22:4
(1)
PC O-16:0/20:4
(1)
PE 16:0/22:6
(1)
PC 20:4/20:4
(1)
PC 16:1/20:4
(1)
PE 18:1/20:4
(1)
PC 16:0/14:0
(1)
PE P-16:0/20:4
(1)
PE P-18:0/20:4
(1)
DAG 18:0/20:4
(1)
TAG 16:0/18:1/18:1
(1)
TAG 16:0/18:1/20:1
(1)
TAG 16:0/16:0/20:4
(1)
TAG 16:1/16:1/18:1 & TAG 16:0/14:0/20:3
(1)
TAG 18:1/18:1/20:1
(1)
TAG 16:1/16:1/18:2
(1)
TAG 16:0/18:1/20:4
(1)
TAG 16:0/18:1/18:2
(1)
MAG 18:0
(1)
PC 42:10
(1)
PE P-18:1/20:4
(1)
PE 18:0/20:4
(1)
PE 16:0/20:4
(1)
PC 16:0/22:6
(1)
PC 16:0/20:3
(1)
PC 16:0/18:2
(1)
PC 16:0/18:1
(1)
PC 16:0/16:0
(1)
PC 32:2
(1)
PC 42:5
(1)
Release Date
2023
(17)
2025
(16)
2022
(15)
2024
(14)
2021
(10)
2020
(3)
2026
(2)
2019
(2)
2018
(2)
2017
(2)
2016
(1)
Previous
page
1 / 9
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
9
Next
page
Sort
by:
Relevance
Page size
10
A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients.
Not available
S-EPMC10092624
|
biostudies-literature
Cite
Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.
Not available
S-EPMC8080595
|
biostudies-literature
Cite
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.
Not available
S-EPMC11694305
|
biostudies-literature
Cite
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Not available
S-EPMC9795751
|
biostudies-literature
Cite
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Not available
S-EPMC9594927
|
biostudies-literature
Cite
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.
Not available
S-EPMC11458988
|
biostudies-literature
Cite
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Not available
S-EPMC10882294
|
biostudies-literature
Cite
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Not available
S-EPMC10542255
|
biostudies-literature
Cite
Mechanical Stimulation Protects Against Chondrocyte Pyroptosis Through Irisin-Induced Suppression of PI3K/Akt/NF-κB Signal Pathway in Osteoarthritis.
Not available
S-EPMC8959944
|
biostudies-literature
Cite
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy.
Not available
S-EPMC8972928
|
biostudies-literature
Cite
Previous
page
1 / 9
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
9
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
